Nuvectra Corporation, a neurostimulation medical device company, develops and commercializes neurostimulation technology platform for the treatment of various disorders in neuroscience and clinical markets. The company offers Algovita, a spinal cord stimulation system for the treatment of chronic intractable pain of the trunk and limbs. It is also developing Virtis, a sacral neuromodulation (SNM) system for the treatment of chronic urinary retention and overactive bladder; and technologies to support other indications, including SNM for the treatment of overactive bladder and deep brain stimulation to treat Parkinson's disease. The company serves hospitals, surgery centers, and medical facilities through a direct sales force and third-party distributors in the United States and Europe. Nuvectra Corporation was founded in 2008 and is headquartered in Plano, Texas.
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Phone214-474-3103
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$48.83 million
Profitability
Miscellaneous
Employees197
Next Earnings Date8/6/2019 (Estimated)
OptionableOptionable
Nuvectra (NASDAQ:NVTR) Frequently Asked Questions
What is Nuvectra's stock symbol?
Nuvectra trades on the NASDAQ under the ticker symbol "NVTR."
How were Nuvectra's earnings last quarter?
Nuvectra Corp (NASDAQ:NVTR) issued its quarterly earnings data on Wednesday, May, 1st. The company reported ($0.83) earnings per share for the quarter, missing analysts' consensus estimates of ($0.65) by $0.18. The company had revenue of $11.13 million for the quarter, compared to the consensus estimate of $12.76 million. Nuvectra had a negative net margin of 98.77% and a negative return on equity of 62.18%. View Nuvectra's Earnings History.
When is Nuvectra's next earnings date?
What price target have analysts set for NVTR?
4 brokerages have issued twelve-month target prices for Nuvectra's shares. Their predictions range from $18.00 to $27.00. On average, they anticipate Nuvectra's share price to reach $21.00 in the next twelve months. This suggests a possible upside of 429.0% from the stock's current price. View Analyst Price Targets for Nuvectra.
What is the consensus analysts' recommendation for Nuvectra?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Nuvectra in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Nuvectra.
Has Nuvectra been receiving favorable news coverage?
Press coverage about NVTR stock has trended positive recently, InfoTrie Sentiment Analysis reports. InfoTrie identifies positive and negative media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Nuvectra earned a daily sentiment score of 2.5 on InfoTrie's scale. They also gave news articles about the company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the company's share price in the near term.
Who are some of Nuvectra's key competitors?
Some companies that are related to Nuvectra include SeaSpine (SPNE), Pulse Biosciences (PLSE), Iradimed (IRMD), Neuronetics (STIM), Cytosorbents (CTSO), Apyx Medical (APYX), Alphatec (ATEC), Liquidia Technologies (LQDA), Endologix (ELGX), iCAD (ICAD), T2 Biosystems (TTOO), Sensus Healthcare (SRTS), RenovaCare (RCAR), Apollo Endosurgery (APEN) and Motus GI (MOTS).
What other stocks do shareholders of Nuvectra own?
Who are Nuvectra's key executives?
Nuvectra's management team includes the folowing people:
- Dr. Fred B. Parks Ph.D., CEO & Director (Age 72)
- Mr. Joseph Paul Hanchin, Pres (Age 57)
- Mr. Walter Z. Berger, COO, CFO & Exec. VP (Age 63)
- Ms. Jennifer J. Kosharek, VP, Controller & Principal Accounting Officer (Age 38)
- Mr. Benjamin Tranchina, Chief Technology Officer
Who are Nuvectra's major shareholders?
Nuvectra's stock is owned by many different of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (6.67%), Gilder Gagnon Howe & Co. LLC (5.75%), Dimensional Fund Advisors LP (4.29%), Cannell Capital LLC (4.06%), Peregrine Capital Management LLC (3.66%) and Wells Fargo & Company MN (3.12%). Company insiders that own Nuvectra stock include Benjamin Tranchina, David D Johnson, Joseph Paul Hanchin, Scott F Drees and Thomas Edward Zelibor. View Institutional Ownership Trends for Nuvectra.
Which institutional investors are selling Nuvectra stock?
NVTR stock was sold by a variety of institutional investors in the last quarter, including Schonfeld Strategic Advisors LLC, BlackRock Inc., Gilder Gagnon Howe & Co. LLC, Peregrine Capital Management LLC, Connor Clark & Lunn Investment Management Ltd., Northern Trust Corp, Parametric Portfolio Associates LLC and Essex Investment Management Co. LLC. View Insider Buying and Selling for Nuvectra.
Which institutional investors are buying Nuvectra stock?
NVTR stock was bought by a variety of institutional investors in the last quarter, including Cannell Capital LLC, Neuberger Berman Group LLC, Wells Fargo & Company MN, Meitav Dash Investments Ltd., Assenagon Asset Management S.A., Marshall Wace LLP, Gabelli Funds LLC and Penn Capital Management Co. Inc.. Company insiders that have bought Nuvectra stock in the last two years include Benjamin Tranchina, David D Johnson, Scott F Drees and Thomas Edward Zelibor. View Insider Buying and Selling for Nuvectra.
How do I buy shares of Nuvectra?
Shares of NVTR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Nuvectra's stock price today?
One share of NVTR stock can currently be purchased for approximately $3.97.
How big of a company is Nuvectra?
Nuvectra has a market capitalization of $70.67 million and generates $48.83 million in revenue each year. The company earns $-48,130,000.00 in net income (profit) each year or ($3.19) on an earnings per share basis. Nuvectra employs 197 workers across the globe.
What is Nuvectra's official website?
How can I contact Nuvectra?
Nuvectra's mailing address is 5830 GRANITE PKWY SUITE 1100, PLANO TX, 75024. The company can be reached via phone at 214-474-3103 or via email at [email protected]
MarketBeat Community Rating for Nuvectra (NASDAQ NVTR)
MarketBeat's community ratings are surveys of what our community members think about Nuvectra and other stocks. Vote "Outperform" if you believe NVTR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NVTR will underperform the S&P 500 over the long term. You may vote once every thirty days.
